# The molecular biology and therapeutic potential of Nrf2 in leukemia

- **DOI:** [10.1186/s12935-022-02660-5](https://doi.org/10.1186/s12935-022-02660-5)
- **Rating:** Limited (2.6 out of 5)
- **Verdict:** A broad leukemia-focused Nrf2 synthesis that organizes preclinical evidence effectively, but one-sided selection leaves its therapeutic conclusions less secure.
- **Framework version:** v5.8
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-08-18
- **Evaluation page:** https://www.nabu.science/paper/10.1186%2Fs12935-022-02660-5

## Key claims

1. Nrf2 protects cancerous cells from apoptosis and increases proliferation, angiogenesis, and metastasis. It promotes resistance to chemotherapy and radiotherapy in various solid tumors and hematological malignancies
   - Support: Supported
   - Type: Primary finding
   - Basis: multiple preclinical leukemia studies support chemoresistance, but the narrative selection method and cross-cancer context limit certainty
   - Location: Abstract
2. Nrf2 and NF-κB work together to control the cellular redox pathway; antagonistic in inflammation, synergistic in leukemia
   - Support: Supported
   - Type: Secondary
   - Basis: cited mechanistic studies support pathway interaction, though the unsystematic narrative synthesis limits confidence in its generality
   - Location: Abstract; Nrf2 and inflammation subsection
3. Nrf2 is a poor prognostic marker in leukemia
   - Support: Unsupported
   - Type: Secondary
   - Basis: the review does not present commensurate clinical prognostic evidence in leukemia
   - Location: Conclusion
4. Inhibition of Nrf2, whether by knockdown techniques, siRNA, or the use of inhibitory compounds, combined with current frontline therapies, stops cell growth and causes apoptosis in malignant cells
   - Support: Tentative
   - Type: Secondary
   - Basis: individual preclinical studies support growth inhibition and apoptosis, but broad generalization beyond tested models remains uncertain
   - Location: Conclusion

## Strengths

- **Broad leukemia subtype evidence map** Table 1 consolidates findings across CML, AML, APL, CLL, and ALL, including study type, experimental model, intervention, and reported result.
  - Dimension: contribution
  - Location: Table 1, pages 13–14
- **Useful pathway interaction framework** The manuscript uses Nrf2–NF-κB interactions to connect redox regulation, inflammation, leukemia progression, and treatment resistance.
  - Dimension: contribution
  - Location: Nrf2 and inflammation subsection; Figures 2 and 4
- **Logical molecular-to-disease organization** The review proceeds from Nrf2 structure and regulation through biological functions and then leukemia-specific evidence, making a long technical discussion navigable.
  - Dimension: reporting
  - Location: Nrf2 structure through leukemia subtype sections

## Limitations

- **Conflicting evidence receives little analysis** The AML section acknowledges studies in which Nrf2 activation may be beneficial but does not compare their mechanisms or implications with the dominant inhibition narrative.
  - Dimension: methodological rigour
  - Location: Nrf2 and Acute myeloid leukemia subsection, page 16
- **No literature selection method reported** No databases, search dates, search terms, or inclusion criteria are reported, leaving the completeness and balance of the literature selection uncertain.
  - Dimension: methodological rigour
  - Location: Entire manuscript; no review methods section
- **Conclusions outrun preclinical evidence base** The Conclusion labels Nrf2 a poor prognostic marker and presents inhibition as promising despite limited clinical evidence and acknowledged context-dependent effects.
  - Dimension: reporting
  - Location: Conclusion; Nrf2 function subsection, pages 6–7

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. The narrative is structurally coherent and contains no primary-data inconsistencies, but central wording in the Abstract and Conclusion is more definitive than the preclinical and context-dependent synthesis supports.
- **Research conduct:** Clean. Ethics, consent, and data availability are appropriately marked not applicable for a narrative review, and no original-data or image-integrity issue was identified. A competing-interests statement was not visible in the supplied text, which is an assessability gap rather than evidence of misconduct.
- **Reference integrity:** Clean. 217 of 218 checkable references verified
  - 221 references in manuscript
  - 3 have no canonical index record — counted, but not index-checkable
  - 1 reference confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
